利奈唑胺治疗耐多药结核病的初步评价  

Treatment outcomes of linezolid for multidrug-resistant tuberculosis:a systematic review and meta-analysis

作　　者：黄海荣[1] 于霞[1] 姜广路[1] 戴广明[1] 马玙[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中国防痨杂志》2011年第5期275-279,共5页Chinese Journal of Antituberculosis

基　　金：北京市科技新星计划2007B039

摘　　要：目的初步评价利奈唑胺治疗耐多药结核(MDR-TB)的有效性与安全性。方法检索Cochrane图书馆临床对照试验库、Pubmed、Embase、CBM、CNKI、Wanfang Date等电子数据库。对符合纳入标准的临床研究进行统计分析。结果共有7个国家的5个临床研究符合纳入标准。分析结果表明,含利奈唑胺的联合化疗方案治疗MDR-TB的合并成功率为82%(95%CI 73%～89%);治疗结果为失败、丢失或死亡的比例分别为2%、5%、11%。血液系统不良反应、神经毒性和胃肠道反应的发生率分别为32%、25%、6%。结论利奈唑胺对耐多药结核病有较好的疗效,但药物不良反应发生率较高。Objective To evaluate the efficacy and safety of linezolid for treating multidrug resistant tuberculosis（MDR-TB）. Methods Cochrane Controlled Trials database,Pubmed,Embase,CBM,CNKI,Wanfang Date and other electronic databases were searched.Clinical studies matched the inclusion criteria would be analysed statistically. Results A total of five clinical studies met the inclusion criteria in seven countries.The results showed that the mean proportion of patients achieving treatment success was 82%（95% CI 73%-89%）;the mean proportion of patients whose outcome were treatment failure,default and death were 2%,5% and 11%,respectively.The incidence rate of adverse events in hematopoietic system and neurotoxicity and gastrointestinal system were 32%,25%,6%,respectively. Conclusion Linezolid against MDR-TB has a good efficacy,but the incidence of adverse events is higher.

关 键 词：结核 抗多种药物性/药物疗法 乙酰胺类 恶唑烷酮类 评价研究 

分 类 号：R52[医药卫生—内科学]